Event

Personalised Medicine: Statistics for Companion Diagnostics

Add to:

PSI Webinar
Personalised Medicine: Statistics for Companion Diagnostics
Date for Webinar: Thursday 4th May. 2-3.30pm UK time

Personalised medicines - which are designed to treat particular groups of patients -  are becoming increasingly prominent. In order to identify patients suitable for treatment a companion diagnostic assay is often needed. The Personalized Medicines Coalition (PMC) recently published an article stating that 25% of NME approved by FDA in 2016 included a companion diagnostic.

This webinar will introduce and examine some of the considerations required for statisticians working in the field of companion diagnostics and will include information from an FDA (CDRH) speaker and perspectives/ case-studies from representatives from both a pharmaceutical company and a diagnostic company.

CLICK HERE TO VIEW THE FLYER

Speakers:

Meijuan Li, CDRH
Peter Cooper, Qiagen
Rachel Hodge, AstraZeneca

Abstracts:

Meijuan Li (CDRH)

Applications of personalized medicine are becoming increasingly prominent. A companion diagnostic assay (CDx) is often desired for patient enrollment in device-drug pivotal clinical trial(s) so that FDA can ensure that appropriate clinical and analytical validation studies are planned and carried out for CDx. However, such a requirement may be difficult or impractical to accomplish. A clinical trial assay (CTA) instead of CDx may be used for patient enrollment in drug-device pivotal clinical trial(s). A supplemental agreement study of CDx and CTA will be required to bridge the clinical results from CTA to CDx. In this webinar, we will discuss statistical challenges in study design and data analysis for bridging study. Particularly, we aimed to provide statistical methods on how to estimate the drug efficacy in CDx intended use population using results from bridging study and CTA-drug pivotal clinical trial.

Peter Cooper (Qiagen)
Perspective from Diagnostic Company

 
Rachel Hodge (Astrazeneca)
Perspective/Case-study from Pharmaceutical Company

To access the recording, please visit the Video-on-Demand Library.

Upcoming Events

Joint PSI, EFSPI & ASA BIOP Webinar: Estimands

PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.

PSI Journal Club: Bayesian Methods

Please join us to hear Jingjing Ye (BeiGene) and Amy LaLonde (Eli Lilly) present their recent work. The webinar will be chaired by Bruno Boulanger (PharmaLex).

Latest Jobs

Senior Principal / Principal Biostatistician

Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.

Statisticians - Oncology

Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.

Therapeutic Area Global Expert Statistician - CNS & Retinopathies

You are looking for a new professional challenge - we offer you this interesting position in a global company that has been awarded several times the status of best employer.